Indaptus Therapeutics, Inc. (INDP )

Currency in USD Disclaimer
$0.34 -$0.01 (-2.4%)
Open 06/02/2025
$0.32
$0.34
$0.31
$2.89

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol INDP
  • Company Indaptus Therapeutics, Inc.
  • Price $0.34
  • Changes Percentage -2.4
  • Change -0.0081
  • Day Low $0.32
  • Day High $0.34
  • Year High $2.89
  • Year Low $0.31
  • Market Cap $6,413,760
  • Price Avg 50 EMA (D) $0.49
  • Price Avg 200 EMA (D) $0.96
  • Exchange NASDAQ
  • Volume 11,744,428
  • Average Volume 629,791
  • Open $0.32
  • Previous Close $0.34
  • EPS -1.48
  • PE -0.27
  • Earnings Announcement 2025-08-11 04:00:00
  • Shares Outstanding $16,034,400

Company brief: INDAPTUS THERAPEUTICS, INC. (INDP )

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

INDP Corporation News

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

June 2, 2025 at 12:00 pm ET

globenewswire.com -- NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections,...

Income Statement